Core Insights - The "Shenzhen Venture Capital Day" focused on early-stage projects in the pharmaceutical and medical device industries, aiming to inject new momentum into Shenzhen's biopharmaceutical innovation ecosystem through a three-dimensional linkage of policy, capital, and industry [1][2]. Group 1: Event Overview - The event featured six pioneering companies in cutting-edge fields such as scar-free healing materials, AI-driven drug development, and nuclear medicine imaging equipment [1]. - Notable companies included Guangzhou Yuanbo Biotech, which has developed a world-first scar-free healing artificial skin using ultra-high molecular weight polyethylene nanomembrane technology [1]. - Other participating companies included Panplona Biotech, which focuses on AI-based drug development for tumors and autoimmune diseases, and Ximu Molecular Imaging, which is innovating nuclear medicine imaging technology [1]. Group 2: Investment and Capital Engagement - The event included three main components: policy interpretation, project roadshows, and capital matching [2]. - Over 20 leading investment institutions, such as Dongfang Fuhai and Lihua Venture Capital, participated, facilitating precise matching of technological value and capital needs through structured presentations [2].